ANEB - Anebulo Pharmaceuticals Inc
NYSE * Health Care * Biotechnology
$0.55
+$0.11 (+25.00%)
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
ANEB Key Statistics
Market Cap
$22.43M
P/B Ratio
2.82
EPS
$-0.18
Employees
2
How ANEB Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
N/A
of 5
Size Rank
#6
of 6
Anebulo Pharmaceuticals Inc Company Information
- Headquarters
- Texas; U.S.A
- Website
- www.anebulo.com
- Sector
- Health Care
- Industry
- Biotechnology